HF
LGND icon

Halpern Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Halpern Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29
Closed -$1.61K – 268
2022
Q2 		$1.61K Buy
+29
New +$1.65K ﹤0.01% 258

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Halpern Financial's LGND Position: Q3 2022 in Review

Halpern Financial sold out of Ligand Pharmaceuticals (LGND) in Q3 2022, closing a stake of 29 shares — an estimated $1.61K sold.

Halpern Financial first reported a position in LGND in Q2 2022 and held it in 1 quarter. The position peaked at $1.61K in Q2 2022. 205 funds tracked by Wall St. Rank hold LGND as of Q3 2022.

  • Halpern Financial reported no remaining Ligand Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Halpern Financial sold 29 Ligand Pharmaceuticals shares in Q3 2022, an estimated $1.61K.
  • Halpern Financial first reported a position in Ligand Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Halpern Financial's Ligand Pharmaceuticals position peaked at $1.61K in Q2 2022.
  • 205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2022.

Based on Halpern Financial's 13F filing for Q3 2022, filed 21 Sep 2023.